Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiester...Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiesterase inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5 (PDE5I) have been used as part of the treatment in certain patients, however, such combination has not been studied or reported before.展开更多
文摘Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiesterase inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5 (PDE5I) have been used as part of the treatment in certain patients, however, such combination has not been studied or reported before.
